Leukemia

• EMA approval · 2026-08-19
  EMA Authorised: Vanflyta (quizartinib dihydrochloride) — Daiichi Sankyo Europe GmbH

  Vanflyta (quizartinib dihydrochloride) has been authorised in Europe for leukemia/myeloid indications.

• EMA approval · 2026-07-17
  EMA Authorised: Inaqovi (cedazuridine;decitabine) — Otsuka Pharmaceutical Netherlands B.V.

  EMA has authorised Inaqovi (cedazuridine/decitabine) for leukemias with myeloid involvement, expanding available treatment options.

• EMA approval · 2026-06-25
  EMA Authorised: Inaqovi (cedazuridine;decitabine) — Otsuka Pharmaceutical Netherlands B.V.

  EMA has authorised Inaqovi (cedazuridine; decitabine) for use in leukemia with a myeloid therapeutic focus.

• EMA approval · 2025-09-25
  EMA Authorised: Xaluprine (previously Mercaptopurine Nova Laboratories) (6-mercaptopurine monohydrate) — Lipomed GmbH

  EMA authorised Xaluprine (6-mercaptopurine monohydrate) by Lipomed GmbH for leukemia/lymphoid indications.

• FDA approval · 2017-12-18
  FDA Approved: BUSULFAN — Original Application (Amneal Pharmaceuticals LLC)

  FDA approved Amneal Pharmaceuticals' busulfan Original Application, establishing a generic version of busulfan for clinical use.

• Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.